CN117120476A - 对结构无序序列具有特异性的抗体 - Google Patents

对结构无序序列具有特异性的抗体 Download PDF

Info

Publication number
CN117120476A
CN117120476A CN202180087405.1A CN202180087405A CN117120476A CN 117120476 A CN117120476 A CN 117120476A CN 202180087405 A CN202180087405 A CN 202180087405A CN 117120476 A CN117120476 A CN 117120476A
Authority
CN
China
Prior art keywords
ala
ser
mab
seq
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087405.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·席尔兹
U·宾德尔
L·弗里德里希
M·格鲍尔
M·施拉普许
A·斯克拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xl Protan Co
Technische Universitaet Muenchen
Original Assignee
Xl Protan Co
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xl Protan Co, Technische Universitaet Muenchen filed Critical Xl Protan Co
Publication of CN117120476A publication Critical patent/CN117120476A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180087405.1A 2020-12-22 2021-12-22 对结构无序序列具有特异性的抗体 Pending CN117120476A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20216744.1 2020-12-22
EP20216744 2020-12-22
PCT/EP2021/087365 WO2022136582A1 (en) 2020-12-22 2021-12-22 Antibodies specific for structurally disordered sequences

Publications (1)

Publication Number Publication Date
CN117120476A true CN117120476A (zh) 2023-11-24

Family

ID=73856935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180087405.1A Pending CN117120476A (zh) 2020-12-22 2021-12-22 对结构无序序列具有特异性的抗体

Country Status (9)

Country Link
US (1) US20240294632A1 (https=)
EP (1) EP4267628A1 (https=)
JP (1) JP2024501316A (https=)
KR (1) KR20230124637A (https=)
CN (1) CN117120476A (https=)
AU (1) AU2021405029A1 (https=)
CA (1) CA3200238A1 (https=)
IL (1) IL303816A (https=)
WO (1) WO2022136582A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117683866A (zh) * 2024-01-22 2024-03-12 湛江中心人民医院 检测细胞中dna的方法
CN118290585A (zh) * 2024-06-04 2024-07-05 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118146384A (zh) * 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
EP4602053A2 (en) * 2022-10-14 2025-08-20 Aikium Inc. Protein scaffolds for disordered regions
WO2025088192A1 (en) * 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
WO2017109087A1 (en) 2015-12-22 2017-06-29 Xl-Protein Gmbh Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CN110891612A (zh) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117683866A (zh) * 2024-01-22 2024-03-12 湛江中心人民医院 检测细胞中dna的方法
CN118290585A (zh) * 2024-06-04 2024-07-05 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用

Also Published As

Publication number Publication date
WO2022136582A1 (en) 2022-06-30
JP2024501316A (ja) 2024-01-11
EP4267628A1 (en) 2023-11-01
AU2021405029A9 (en) 2025-03-13
AU2021405029A1 (en) 2023-07-20
KR20230124637A (ko) 2023-08-25
US20240294632A1 (en) 2024-09-05
CA3200238A1 (en) 2022-06-30
IL303816A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7158403B2 (ja) Ｂ７－ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
CN117120476A (zh) 对结构无序序列具有特异性的抗体
US20210230269A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
Hong et al. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies
KR102474765B1 (ko) 항-TNFα-항체 및 이의 기능성 단편
JP7419238B2 (ja) Ｐｄ１結合剤
KR20150014996A (ko) 항-토파시티닙 항체 및 약물을 모니터링하기 위한 그의 용도
JP2013538566A (ja) 改良された抗血清アルブミン結合変異体
KR102470235B1 (ko) 항-TNFα-항체 및 이의 기능성 단편
WO2016100533A2 (en) Intercalated single-chain variable fragments
JP2023530663A (ja) 抗ＴＧＦβ抗体及びその治療的使用
EP2944654A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
Schilz et al. Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope
WO2001030393A2 (en) Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
CN121152800A (zh) 特异性结合Claudin18.2的抗体及其制法和应用
WO2019075392A1 (en) ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF
CN116390945A (zh) 无细胞抗体工程化平台和针对SARS-CoV-2的中和抗体
US20250154688A1 (en) Feline antibody library
CN119080939A (zh) 单克隆抗体及其在制备检测喜树碱类化合物与蛋白复合物的试剂中的应用
CN117836308A (zh) 用于选择特异性结合剂的手段和方法
CN121609799A (zh) 一种抗pd-l1的纳米抗体、含其的双特异性重组蛋白及其应用
Chen et al. Engineered antibody domains as candidate therapeutics
HK1262399A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4350345A2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
NZ617995A (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination